Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (81-90 of 250) with videos related to

Pageof 25
Sort By:
Therapeutic Advances in Neurological Disorders|February 6, 2018
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension studyGiancarlo Comi, Stuart Cook, Kottil Rammohan, et al.
Journal of Neurology|January 8, 2013
Clinical effects of natalizumab on multiple sclerosis appear early in treatment courseLudwig Kappos, Paul W O'Connor, Christopher H Polman, et al.
Multiple Sclerosis and Related Disorders|June 11, 2026
Validation and psychometric properties of the Multiple Sclerosis Autonomy Score (MSAS) in a French cohort: The FOCAL-MS 2 studyCécile Donzé, Claude Mekies, Catherine Mouzawak, et al.
The Journal of Rheumatology|April 4, 2006
Myelopathies secondary to Sjögren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroidsJerome de Seze, Sophie Delalande, Anne-Laure Fauchais, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 4, 2018
Proinflammatory B-cell profile in the early phases of MS predicts an active diseaseThomas Guerrier, Myriam Labalette, David Launay, et al.
Journal of Neurology|June 1, 2010
4H syndrome: a rare cause of leukodystrophyOlivier Outteryck, David Devos, Patrice Jissendi, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 4, 2024
Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot studyJérôme de Seze, Christine Clerc, Matthieu Béreau, et al.
Neurology and Therapy|April 8, 2024
Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple SclerosisJerome de Seze, Dominique Dive, Xavier Ayrignac, et al.
Journal of Neurology|June 5, 2015
Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of lifeEtienne Allart, Anne Benoit, Anne Blanchard-Dauphin, et al.
Neurology and Therapy|November 20, 2023
Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple SclerosisPierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, et al.
Pageof 25

Showing results (81-90 of 250) with videos related to

Sort By:
Pageof 25
Therapeutic Advances in Neurological Disorders|February 6, 2018
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension studyGiancarlo Comi, Stuart Cook, Kottil Rammohan, et al.
Journal of Neurology|January 8, 2013
Clinical effects of natalizumab on multiple sclerosis appear early in treatment courseLudwig Kappos, Paul W O'Connor, Christopher H Polman, et al.
Multiple Sclerosis and Related Disorders|June 11, 2026
Validation and psychometric properties of the Multiple Sclerosis Autonomy Score (MSAS) in a French cohort: The FOCAL-MS 2 studyCécile Donzé, Claude Mekies, Catherine Mouzawak, et al.
The Journal of Rheumatology|April 4, 2006
Myelopathies secondary to Sjögren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroidsJerome de Seze, Sophie Delalande, Anne-Laure Fauchais, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 4, 2018
Proinflammatory B-cell profile in the early phases of MS predicts an active diseaseThomas Guerrier, Myriam Labalette, David Launay, et al.
Journal of Neurology|June 1, 2010
4H syndrome: a rare cause of leukodystrophyOlivier Outteryck, David Devos, Patrice Jissendi, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 4, 2024
Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot studyJérôme de Seze, Christine Clerc, Matthieu Béreau, et al.
Neurology and Therapy|April 8, 2024
Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple SclerosisJerome de Seze, Dominique Dive, Xavier Ayrignac, et al.
Journal of Neurology|June 5, 2015
Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of lifeEtienne Allart, Anne Benoit, Anne Blanchard-Dauphin, et al.
Neurology and Therapy|November 20, 2023
Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple SclerosisPierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, et al.
Pageof 25